Efficacy and safety of bulevirtide in patients with chronic hepatitis D treated under early access in Switzerland: a retrospective analysis
{{output}}
BACKGROUND AND AIMS: Bulevirtide 2 mg/day was approved in Switzerland in February 2025 for the treatment of chronic hepatitis D virus (HDV) infection. We present real-world data on efficacy and safety in patients treated under an early access programme. ... ...
